David A. Braun

Yale New Haven Hospital — United States

Medicine · Health Sciences

36h-index7.3kcitations453works2.52yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(271), Renal cell carcinoma treatment(220), Cancer Genomics and Diagnostics(87), Renal and related cancers(65), Cancer Diagnosis and Treatment(62)

Publications453 total

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

UNC Libraries·2025Open Access

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

CA A Cancer Journal for Clinicians·2025Open Access

Figure S6 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

2025Open Access

Table S2 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

2025Open Access

Supplementary Data from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

2025Open Access

Table S3 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

2025Open Access

Figure S11 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

2025Open Access

Figure S10 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

2025Open Access

Figure S7 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

2025Open Access

Figure S1 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

2025Open Access

Figure S12 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

2025Open Access

Figure S8 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

2025Open Access

Table S1 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

2025Open Access

Figure S2 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

2025Open Access

Figure S9 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

2025Open Access

Figure S5 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

2025Open Access

Figure S4 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

2025Open Access

Figure S3 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

2025Open Access

Survival of patients with metastatic renal cell carcinoma with or without brain metastases

The Oncologist·2025Open Access

119 Endogenous retroviruses as tumor-specific antigens in clear cell renal cell carcinoma: A new avenue for immunotherapy

Regular and Young Investigator Award Abstracts·2025Open Access

page 1 of 23Next →

Frequent Co-authors

Toni K. Choueiri(35), Sabina Signoretti(22), Catherine J. Wu(18), Sachet A. Shukla(16), Eliezer M. Van Allen(15), David F. McDermott(14), Wanling Xie(13), Ziad Bakouny(12), Bradley A. McGregor(12), John A. Steinharter(11), Abdallah Flaifel(10), Rana R. McKay(10), Thomas Denize(9), Amin H. Nassar(9), Lauren C. Harshman(9), Gordon J. Freeman(8), Derin B. Keskin(8), Xiao X. Wei(8), Megan Wind‐Rotolo(7), Pier Vitale Nuzzo(7)